Upper tract urothelial carcinoma (UTUC) is relatively rare and accounts for approximately 5% of all urothelial carcinomas. The estimated annual incidence of UTUC in Western countries is about two new cases per 100,000 inhabitants. The management of patients with upper tract urothelial carcinomas has changed significantly over the last decade with improved diagnostic techniques and treatment options. The gold-standard treatment used to be open radical nephroureterectomy with removal of the ipsilateral bladder cuff. The use of minimally invasive techniques for the diagnosis and management of upper urinary tract urothelial carcinoma is however expanding and has led to a paradigm shift in treatment strategies of upper tract urothelial carcinomas. In this article, we review the current diagnostic modalities and various endoscopic techniques being currently used in the management of this relatively rare tumour.
Introduction
Urothelial carcinomas can be located in the upper or lower urinary tract. Upper tract urothelial carcinoma (UTUC) is relatively uncommon and accounts for approximately 5% of all urothelial carcinomas. 1 The estimated annual incidence of UTUC in Western countries is about two new cases per 100,000 inhabitants. 2 They can arise at any location from the urothelial lining of the renal calyces to the distal ureter. Compared to urothelial carcinomas of the bladder, upper tract tumours are more advanced at initial diagnosis, with about 60% presenting with invasive disease. 3 The prognosis is therefore poorer and depends mainly on the stage at diagnosis. Risk factors for UTUC include tobacco smoking and occupational exposure. In addition, nephropathy due to Chinese herbs and Balkan endemic nephropathy are also associated with a higher risk of developing UTUC. 4 There is also a possible association of UTUC with blackfoot disease and arsenic exposure in drinking water in Taiwan. 5 Increased risk for UTUC is described for patients with Lynch syndrome, caused by mutations in mismatch repair genes. 6 The management of patients with UTUCs has changed significantly over the last decade with improved diagnostic techniques and treatment options. The gold-standard treatment has been open radical nephroureterectomy (ONU) with removal of the ipsilateral bladder cuff. 7 With the recent advances in minimally invasive surgical techniques and earlier diagnosis of lower stage tumours, laparoscopic and endoscopic surgical options are attractive alternatives and are now being increasingly used in the management of patients with UTUC. This is due to decreased morbidity, improved cosmesis and shorter recovery times. In this review, we aim to analyse the role and value of the current diagnostic modalities and endoscopic techniques in the treatment of UTUC.
Diagnosis
The most common presenting symptoms of UTUCs include frank or microscopic haematuria in 70%-90% and loin pain in about 30% of patients. 8 A flank mass is seen in 10%-20% of cases. 2 Fifteen per cent of patients do not experience any symptoms and are diagnosed with incidental UTUC on imaging studies. 9 Systemic symptoms such as reduced appetite and weight loss are present only in the presence of advanced metastatic disease.
Patients presenting with haematuria should therefore be appropriately investigated. They require an assessment of their whole urinary tract to find a cause for their symptom. The lower urinary tract is assessed with cystoscopy while the upper tracts are usually evaluated with different imaging modalities such as ultrasonography (US), computed tomography (CT) or magnetic resonance imaging (MRI). Direct visualisation of the upper tracts with biopsy of any suspicious areas is now also possible with modern endoscopic technology through rigid or flexible ureteroscopy (URS). With the development of minimally invasive nephron-sparing surgical techniques, accurate radiological diagnosis and staging are essential so that the most appropriate treatment option can be chosen, particularly in patients with poorly functioning kidneys.
US
Renal USs are sometimes requested to evaluate patients with haematuria and exclude renal parenchymal masses. However, ultrasound is not as sensitive as CT in detecting and characterising renal masses. The detection rate of renal pelvis tumours using US is about 82% in the literature, but can be as low as 12% for urothelial carcinomas of the ureter. 2 Its role is therefore limited in the evaluation of the ureter and peri-ureteric tissues. US can, however, detect hydronephrosis, which can be a sign of obstruction due to ureteric tumours. It can still be used in patients with renal impairment or allergies to contrast, although MR urography (MRU) is being increasingly used in such patients. MRU without gadolinium contrast is recommended in patients with a history of previous reaction to iodinated contrast material or renal insufficiency. 10 With CT urography (CTU) becoming the initial imaging investigation of choice in patients presenting with haematuria, US will likely play a limited diagnostic role in the future. 11 
CT
Multiphasic CTU has the highest diagnostic accuracy for UTUC with a sensitivity ranging from 0.67 to 1.0 and specificity of 0.93 to 0.99. 12 It can also detect urinary tract calculi and small renal masses. Three-dimensional reconstruction of the image data is now possible for better visualisation of the pathology in case surgical intervention is being planned. It may also allow differentiation of urothelial carcinomas from calculi or clots, although it can sometimes be difficult to differentiate advanced renal urothelial carcinomas from renal cell carcinomas based on CT appearances alone. Flat ureteric lesions can be difficult to identify on CTU unless there is associated wall thickening and peri-ureteric fat stranding. 11 It is also impossible to accurately assess the depth of tumour invasion based on CT images alone. Compared to US, it is associated with increased radiation exposure and is more time-consuming. As mentioned above, CTU is contraindicated in patients with renal impairment or contrast allergies. It has nonetheless become the firstline investigation of choice to evaluate patients with suspected UTUC.
MRI
Magnetic resonance urography (MRU) is not the primary investigation for patients presenting with haematuria. It can however be used in patients who are allergic to iodinated contrast agents used for CTU. The sensitivity of MRU for tumours less than 2 cm after contrast administration is reported to be 0.75. 13 With the development of faster sequences, it is equal to CT in the detection of renal masses although more time-consuming due to the requirement for multiple sequences. 11 For evaluation of UTUC, MRU may be static or dynamic by using gadolinium contrast. Gadolinium is however contraindicated in patients with severe chronic renal impairment, and retrograde uretero-pyelogram is preferred in those patients. Threedimensional evaluation of abnormal areas is also possible with MRU. One of its main advantages is the lack of radiation exposure compared to CTU. However, it is unable to reliably detect urinary tract calculi, which limits its use as the first-line investigation for haematuria. As with CT, it may also miss flat or small tumours due to motion artefacts. 14 
Endoscopy
In patients presenting with haematuria, it is important to identify all possible tumours in both the lower and upper urinary tracts so that they can be staged and managed appropriately. Cystoscopy and ureteroscopy with or without biopsies will help confirm the presence of any malignancy. At the time of cystoscopy, retrograde uretero-pyelography (RPG) can also be carried out. This can help identify any filling defects in the ureter or renal pelvis. Its diagnostic sensitivity and specificity is comparable to CTU for detecting filling defects. 15 However, it is more invasive than CTU and is not always necessary unless ureteroscopy and biopsy of abnormal areas is needed for histological confirmation before planning treatment. Ureteroscopy allows direct visualisation of the upper tracts including any filling defects visible on RPG. Small-calibre ureteroscopes with active deflecting mechanisms and better optics provide important diagnostic information by allowing closer visual inspection and biopsy of suspicious areas. 9 One study has shown that ureteroscopic appearance was only 70% accurate in determining the grade of upper tract urothelial lesions 16 whereas the specificity of ureteroscopic-guided biopsy for determining tumour grade was between 75% and 92%. 17 One potential problem of ureteroscopic biopsy of UTUC is the difficulty in obtaining accurate staging information. Due to the reduced wall thickness of the upper tracts and the small size of the biopsies obtained, it can be difficult to assess the depth of tumour invasion. Whilst there is a clear role for biopsies in grade prediction, biopsy stage cannot reliably predict histopathological stage. 18 Biopsy grade appears to be a strong predictor for histopathological stage with around 70% of Grade 1 biopsies correctly predicting non-invasive stage (⩽pT1) and around 70% of Grade 3 biopsies correctly predicting invasive stage (≥pT2). 19 A combination of radiological imaging as well as endoscopic appearance and biopsy results is necessary to obtain the most accurate tumour staging prior to treatment. 20 Ureteroscopy however remains an invasive procedure with associated morbidity and potential risk of tumour seeding. 21 
Disease management
Open radical nephroureterectomy with excision of a bladder cuff surrounding the ipsilateral ureteric orifice has been the standard treatment for UTUCs in patients with normal contralateral kidneys. 8 This approach is however being challenged by the recent advances in technology and minimally invasive laparoscopic surgical techniques. Conservative endoscopic management via retrograde or percutaneous antegrade approaches as well as nephron-sparing surgery are now feasible alternatives, even in patients with normal contralateral kidneys. 22 Accurate staging by combining cross-sectional imaging techniques and endoscopic evaluation with biopsy is key to selecting the most appropriate treatment option. 7 According to the European Association of Urology (EAU) guidelines on UTUC, the indications for endourological management include unifocal low-grade tumour, which is less than 1 cm with no evidence of infiltration on CTU. 12 The patient also needs to be aware of the need for close follow-up.
Laparoscopic radical nephroureterectomy (LNU)
LNU was first reported in 1991. 23 LNU is now gradually replacing ONU due to lower blood loss, reduced postoperative pain and shorter hospital stays. 24 Invasive or large tumours are contraindications for the laparoscopic approach. The laparoscopic approach can be either retroperitoneal or transperitoneal. The removal of the distal ureter and bladder cuff is once again an important step of the whole procedure. LNU should take place in a closed system and care should be taken to avoid entering the urinary tract and prevent tumour spillage. An open approach, although a compromise to the laparoscopic technique, can be used to access the distal ureter and bladder and prevent spillage, whereas the pluck techniques can increase the risk of local recurrence. 25 Laparoscopic stapling of the distal ureter and bladder can avoid tumour spillage, but viable tissue can remain in the staple line and make the surgical margin difficult to evaluate. 26 No prospective data are currently available comparing the different techniques. A retrospective study of 116 patients, however, showed no difference in recurrence rates between the different laparoscopic techniques. 27 The pluck procedure involves an endoscopic resection of the ureteric orifice and its intramural tract until the perivesical fat is visualised. Coagulation of the resected area and of the ureteric stump is then carried out before an indwelling urethral catheter is inserted. The dissection of the distal ureter and its release from the bladder wall is subsequently easier to perform. The pluck technique is contraindicated in tumours of the distal or intramural ureter. The rates of recurrence for bladder tumours after open removal of the distal ureter are around 30% and the risk of tumour spillage is low. 28 A comparison at nearly four years after LNU showed an increased positive margin rate and local recurrence rate, and decreased recurrence-free survival rates were observed in the laparoscopic-stapled group when compared with the open group. 29 A higher incidence of positive surgical margins (up to 25%) and local recurrence (up to 15%) have been reported in the pure LNU with laparoscopic stapling group. 30 Only 11 cases of port-site metastases have been reported in the literature to date. 24 In most of the cases, no organ bag was used for specimen retrieval or the bag was torn. Retrieval bags should therefore always be used, especially if high-grade disease is suspected and the specimens should not be morcellated.
Initially, only short-term data were available when comparing ONU and LNU. Only a limited comparison between the two techniques could therefore be made. The first multi-centre study looking at LNU was published in 2002. 27 It showed that the two-year disease-specific survival (DSS) was 87%. In 2004, a study of 64 patients comparing ONU and LNU, with a mean follow-up of 96 and 101 months respectively, showed that the overall survival was similar in both groups. 31 The studies are limited by their relatively small sample size. A subsequent meta-analysis 32 showed that five-year DSS was 81.2% for LNU and 61% for ONU. However, more studies have been published since, including data on oncological outcomes. A large retrospective multi-centre study has shown that the oncological safety of both techniques were similar. 33 This was confirmed in a systematic review published in 2012. 34 To date, only one prospective randomised study has shown that LNU is not inferior to ONU. 35 LNU has been shown to be associated with reduced blood loss, shorter hospital stays and early return to normal activities, despite a longer operating time. 7 LNU is therefore considered as a viable and oncologically safe alternative to the open approach. With the recent advancements in laparoscopic surgery and given the findings from the above-mentioned studies, LNU has arguably become the new gold-standard treatment for UTUCs.
Endoscopic nephron-sparing techniques
With improvements in flexible fibre-optic instruments and advances in laser technology, endoscopic management of UTUCs has become another alternative. The endoscopic approach was initially recommended for small, low-grade non-invasive tumours in co-morbid patients with solitary kidneys, renal impairment or bilateral disease. 36 It may spare the patients the morbidity of radical surgery especially in non-invasive disease, while preserving renal function and maintaining oncological results in the short and medium term as far as disease-specific survival is concerned. 12 Endoscopic approach can be ureteroscopic (retrograde) or percutaneous (antegrade).
Ureteroscopic management
A retrograde approach using a semi-rigid ureteroscope is the most common endoscopic modality used to treat ureteric urothelial carcinomas. This technique was first described in 1985. 37 For tumours difficult to access in the upper ureter or in the renal pelvis, a flexible ureteroscope can be used. Modern scopes now allow a deflection angle of up to 270 degrees for tumours located in the lower pole calyx. For tumour ablation, holmium or neodymium:yttrium-aluminium-garnet lasers are most frequently used. Initially used for diagnostic purposes, ureteroscopy is now a common therapeutic modality. The risks of ureteroscopic treatment include the risks of ureteric perforation or avulsion causing extraluminal tumour spillage, ureteric strictures and residual disease. There is also a risk of subsequent tumour upstaging and progression requiring radical nephroureterectomy. 38 The advantages of the ureteroscopic approach include preservation of renal function, reduced morbidity, shorter hospital stay as well as avoiding over-treatment for lowgrade non-invasive disease. Disadvantages include inability to treat larger tumours in one session, difficulty accessing upper ureteric or lower calyx tumours and under-staging tumours. This is because the modern smallcalibre ureteroscopes allow only limited tissue sampling. Similarly, the small visual field can make tumour ablation difficult resulting in incomplete ablation and residual disease. Initial staging investigations are therefore essential to ensure the correct treatment modality is being used.
Ureteroscopic treatment is not used for high-grade tumours unless used as a palliative modality. This is because studies have shown higher rates of recurrence and disease progression in those cases. 39 The outcomes of the ureteroscopic approach are dependent on the grade of the disease. In one study, the authors found that the five-year DSS was 100% for Grade 1 tumours, 62.5% for Grade 2 disease and 55.6% for Grade 3. 40 The DSS outcomes for Grade 1 disease when treated endoscopically were similar to those from laparoscopic nephroureterectomy. Ureteroscopic treatment for unifocal low-grade tumours less than 1 cm is therefore a suitable alternative to radical surgery. 12 Pure conservative management is nevertheless associated with a risk of under-staging the disease and recurrences can occur even after five years. It is essential to inform the patients of the need for closer and more stringent surveillance, often lifelong, if they have opted for conservative management with the ureteroscopic approach.
Percutaneous management
Percutaneous access to the collecting system is used to treat larger tumours in the renal pelvis or proximal ureter and tumours not accessible via the retrograde ureteroscopic approach. It can also be used in patients who have had a previous cystectomy for bladder carcinoma with urinary diversion. Although retrograde access is possible in those patients, it can be very challenging. The advantages of the percutaneous approach include better visualisation through the use of larger instruments, access to any location in the collecting system, treatment of large tumours in one session and faster resection with the ability to take deeper biopsies for accurate staging. Adjuvant treatment can also be administered through the nephrostomy tube left in the collecting system at the end of the procedure. The same tract can be used for repeated procedures. One study has shown a recurrence rate of about 18% for low-grade tumours and 50% for high-grade disease.
The main complications and risks of the percutaneous approach include bleeding requiring blood transfusions, obstruction of the pelvi-ureteric junction from stricture, surrounding organ and pleural injury. There is also a risk of tumour cell seeding along the tract due to the disruption of the collecting system to gain entry. Rastinehad and colleagues, in their largest series to date, report on their experience with the percutaneous approach in 89 patients (133 renal units) between 1985 and 2005. 41 At a mean follow-up of 61 months, there was only one case of percutaneous tract seeding (0.75%). The incidence of local recurrence was 33%, with an overall survival of 68%. Although more invasive, the outcomes of percutaneous surgery are similar to ureteroscopic treatment. The percutaneous approach is being used less with technological advances and the development of flexible ureteroscopes with increased active deflection. However, in both endoscopic approaches, under-staging remains a significant risk. As a result, endoscopic approaches are reserved for low-grade non-invasive disease and older co-morbid patients with single kidneys or renal impairment.
Adjuvant therapy following endoscopic treatment
Mitomycin-C (MMC) and bacillus Calmette-Guérin (BCG) are administered intravesically to patients with superficial bladder urothelial carcinoma to prevent disease recurrence and progression. One might therefore expect similar results in the context of UTUC. However, given the lack of randomised controlled trials, there is limited evidence supporting the use of those agents.
Adjuvant topical therapy such as MMC and BCG can be delivered retrogradely through a ureteric catheter following ureteroscopic tumour ablation, antegradely though a nephrostomy tube or by reflux up an indwelling ureteric stent. It is difficult to isolate the agents in the upper urinary tract and there is currently no clear guidance regarding the dosage, frequency of instillation or instillation time in the management of UTUCs.
In a study analysing the use of adjuvant BCG after percutaneous management of UTUC, there was no statistical difference between the two groups with regards to recurrence rates and progression of disease. 42 In another study where the authors analysed their 20-year experience with percutaneous resection of UTUC, no oncological benefit was found in the administration of adjuvant BCG. 41 Similarly, another study on the use adjuvant MMC after endoscopic management has shown a recurrence-free survival rate of 53.8% in the group who received adjuvant treatment and 54.2% for patients without treatment. 18 There is currently no clear evidence regarding the use of adjuvant therapy following conservative management of UTUC and further studies are therefore needed.
Conclusion
The use of minimally invasive surgical techniques for the diagnosis and management of UTUC is expanding. LNU has gradually replaced open surgery due to its comparable oncological efficacy and improved peri-operative outcomes. Further technological advances and improvements in endoscopic techniques have also contributed to a move towards nephron-sparing surgery in the treatment of UTUC in co-morbid patients as well as in those with contralateral normal upper tracts. Various studies have shown that the ureteroscopic and percutaneous approaches are feasible with similar disease-specific survival outcomes in highly selected patients with low-grade disease without worsening the cancer-specific mortality. However, patients should be selected carefully for nephron-sparing techniques and should include patients who are highly motivated and compliant as lifelong surveillance is necessary. Robust evidence is still lacking with regards to the cohort of patients who can be best managed with endoscopic techniques. Questions also still exist about the role of adjuvant therapy in the management of UTUC. Larger prospective randomised trials with long-term follow-up data are therefore needed to answer the above questions before we can fully evaluate the place of the above-mentioned treatment methods in the management of UTUCs.
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